Neuraxis (NRXS) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Neuraxis (NRXS) is Moderate Underperform.

The composite score behind that read is -0.21, weighing +0.31 of bullish evidence against -0.36 bearish.

Neuraxis last closed at $7.15, +0.56% on the session.

Against the IVW growth benchmark the position is -0.36% over the forecast window.

The read is built from 12 underlying insights — 2 bullish and 10 bearish.

Agreement across those insights is 83%.

16 graded predictions for NRXS so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Neuraxis in the 6th percentile on return on equity, where 100 is best.

Neuraxis is classified under Health Care / Health Care Equipment & Supplies, with a market capitalisation of $89.29M.

StockMap tracks Neuraxis as the 103rd largest of the 133 companies it covers in the Health Care Equipment & Supplies industry, part of the Health Care sector.

Across that group the current two-week reads are 67 Neutral, 61 Moderate Underperform, 4 Strong Underperform and 1 Moderate Outperform.

On that composite Neuraxis ranks 74th of 133 in the group, against a group median of -0.21.